The Motley Fool on MSN1d
Is Viking Therepautics a Buy Now?
Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing ...
Viking Therapeutics stock falling amid results for new GLP-1 pill
Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and ...
Why Viking Therapeutics Stock Plummeted After Soaring Today
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
Should you buy Viking Therapeutics (VKTX) after today’s spike?
Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.
Viking Therapeutics (VKTX) Gets a Buy from Truist Financial
Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...
Hosted on MSN1d
Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat
Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...